The small-molecule innovative drug developer Lynk Pharma (凌科药业) announced that it has received tens of millions of US dollars in Series A financing round before the Spring Festival this year. The investment was led by Decheng Capital, joined by Zheshang Group and existing investors Mifang Capital and Kaitai Capital.
The proceeds from this round of financing will be mainly used to promote the IND application of multiple preclinical projects in the R&D pipeline of Lynk Pharma, and 2-3 clinical phase I trials. In addition, the company will use the funds raised to promote the development of new projects and international cooperation.
Lynk Pharma is a R&D biopharmaceutical innovation company of small-molecule drug, focusing on cancer and autoimmune diseases. Currently, it mainly focuses on cancer, immunity and inflammation and other disease areas, developing new drug projects through various forms such as independent research and development, technology licensing and technology export from overseas major pharmaceutical companies, and cooperative development.
In March 2018, Lynk Pharma completed an angel round of financing of nearly USD 10 million led by Kaitai Capital, and joined by Mifang Capital and Sinopharm Capital.